~~<i id='09215353FC'><strike id='09215353FC'><tt id='09215353FC'><pre id='09215353FC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

hotspot

author：fashion 2025-09-30 15:23:05 - browse：92

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Readout Newsletter: What happened with Sarepta's Duchenne data

hotspot

explore

focus

entertainment

ImagesshowingdifferencesingraymattervolumebetweenBlackandwhitechildren(top)andshowingthedifferencesa

WSS

Physician subsidies by hospitals soar in wake of No Surprises Act

Readout Newsletter: XBI biotech index, Akero Therapeutics

Sepsis can kill a child within hours. Here's how hospitals are fighting back

CDC recommends rationing of RSV shot due to shortages

Primary care doctor shortage won't be solved by free med school tuition

First Opinion Podcast: How to protect health care in times of war

entertainment

hotspot

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

How to save PrEP access — and even expand it

Brain technologies pose threats that are all too real, experts warn

In Memoriam: Notable people who died in 2023

Chimpanzees, like humans and whales, get menopause: Study

In Memoriam: Notable people who died in 2023

Warren pushes Witty on UnitedHealth's control over physicians

New air purifier tech could be key to improving indoor air quality

Hospitals warn Medicare's drug payment fix is ‘unlawful’

hotspot

PBM executives asked to testify by House panel

FDA has safety concerns on CRISPR

Paying for Covid pills will soon shift to insurers

Biden's order seeks to regulate AI risk without stifling innovation

Most antidepressants don't work on kids, teens, study finds

Chimpanzees, like humans and whales, get menopause: Study

explore

focus

focus

entertainment